Early potassium response to mineralocorticoid receptor antagonist therapy and cardiovascular outcomes in primary aldosteronism: a landmark cohort study

Background Mineralocorticoid receptor antagonists (MRAs) are standard therapy for primary aldosteronism (PA). Serum potassium is measured in nearly every treated patient, but the long-term prognostic value of potassium attained early after initiation is undefined. Methods In the TriNetX Research Network, we identified adults with PA newly initiating spironolactone or eplerenone in 2000-2025, without prior adrenalectomy (n=4,169; 180-day landmark design). Achieved potassium (last value on days 14-180) was categorised as <4.0, 4.0-<4.5, 4.5-<5.0 and ≥5.0 mmol/L, and its change from baseline in tertiles, using cause-specific Cox and Fine-Gray models. The primary outcome was a composite of myocardial infarction, stroke or death; incident heart failure was co-primary. Findings Over a median 3.0 years, 623 composite events occurred. Estimated risk was lowest at 4.5-<5.0 mmol/L (adjusted hazard ratio 0.65, 95% CI 0.52-0.83, versus <4.0 mmol/L), lower than the 4.0-<4.5 mmol/L band, and not different from ≥5.0 mmol/L. A larger rise in potassium was associated with lower risk. A similar pattern was seen for incident heart failure (0.54, 0.36-0.80; 248 events). Potassium below the 3.6 mmol/L consensus threshold for hypokalaemia carried no significantly higher risk (1.22, 0.96-1.56). The change in potassium correlated weakly with the change in renin (rho = 0.15). Interpretation In MRA-treated PA, cardiovascular and heart-failure risk was lowest at an early achieved potassium of 4.5-<5.0 mmol/L, well above the 3.6 mmol/L accepted by consensus criteria as correction of hypokalaemia; correction alone may therefore be an insufficient treatment target. Whether titrating therapy towards this band improves outcomes requires prospective evaluation.

Authors

Institutions

Publication Details

Journal
medRxiv
Published
2026-11-17
DOI
https://doi.org/10.64898/2026.11.15.26368152
Primary Topic
Hormonal Regulation and Hypertension
Type
preprint

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Early potassium response to mineralocorticoid receptor antagonist therapy and cardiovascular outcomes in primary aldosteronism: a landmark cohort study

Yuan-Kai Pang, Chi‐Jung Huang, Szu-Han Chen, Hao-min Cheng et al.
1 links
medRxiv
Hormonal Regulation and Hypertension
preprint

Early potassium response to mineralocorticoid receptor antagonist therapy and cardiovascular outcomes in primary aldosteronism: a landmark cohort study

Yuan-Kai Pang, Chi‐Jung Huang, Szu-Han Chen, Hao-min Cheng, Yun-Yu Chen, Yu-Hsuan Lee, Yen Hsun Huang, Shu-Mei Yang
preprint en

Abstract

Background Mineralocorticoid receptor antagonists (MRAs) are standard therapy for primary aldosteronism (PA). Serum potassium is measured in nearly every treated patient, but the long-term prognostic value of potassium attained early after initiation is undefined. Methods In the TriNetX Research Network, we identified adults with PA newly initiating spironolactone or eplerenone in 2000-2025, without prior adrenalectomy (n=4,169; 180-day landmark design). Achieved potassium (last value on days 14-180) was categorised as <4.0, 4.0-<4.5, 4.5-<5.0 and ≥5.0 mmol/L, and its change from baseline in tertiles, using cause-specific Cox and Fine-Gray models. The primary outcome was a composite of myocardial infarction, stroke or death; incident heart failure was co-primary. Findings Over a median 3.0 years, 623 composite events occurred. Estimated risk was lowest at 4.5-<5.0 mmol/L (adjusted hazard ratio 0.65, 95% CI 0.52-0.83, versus <4.0 mmol/L), lower than the 4.0-<4.5 mmol/L band, and not different from ≥5.0 mmol/L. A larger rise in potassium was associated with lower risk. A similar pattern was seen for incident heart failure (0.54, 0.36-0.80; 248 events). Potassium below the 3.6 mmol/L consensus threshold for hypokalaemia carried no significantly higher risk (1.22, 0.96-1.56). The change in potassium correlated weakly with the change in renin (rho = 0.15). Interpretation In MRA-treated PA, cardiovascular and heart-failure risk was lowest at an early achieved potassium of 4.5-<5.0 mmol/L, well above the 3.6 mmol/L accepted by consensus criteria as correction of hypokalaemia; correction alone may therefore be an insufficient treatment target. Whether titrating therapy towards this band improves outcomes requires prospective evaluation.

medRxiv
National Yang Ming Chiao Tung University (TW), Taipei Veterans General Hospital (TW), Taichung Veterans General Hospital (TW)
Taipei Veterans General Hospital, National Science and Technology Council
Good health and well-being
Hormonal Regulation and Hypertension
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon